Skip to content

Nuvalent, Inc. NUVL Investing Cash Flow

Investing Cash Flow at other companies

Pfizer logo
PfizerPFE
$785M-76.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$31.65M-867%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$238K-100%
Exelixis logo
ExelixisEXEL
-$51.07M-203%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$172.62M+1,182%
Incyte logo
IncyteINCY
-$88.2M-8,140%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s investing cash flow?
Nuvalent, Inc. (NUVL) reported investing cash flow of -$19.41M in Q1 2026.
How has Nuvalent, Inc.'s investing cash flow changed year-over-year?
Nuvalent, Inc.'s investing cash flow decreased by 176.4% year-over-year, from $25.42M to -$19.41M.
What is the long-term trend for Nuvalent, Inc.'s investing cash flow?
Over 3 years (2021 to 2025), Nuvalent, Inc.'s investing cash flow has grown at a -17.4% compound annual growth rate (CAGR), from -$220.03M to -$124.08M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.